Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
clinical deterioration | clinical improvement | deaths | PCR-negative conversion | |||
acetylcysteine | 0 | - | - | - | - | |
alpha lipoic acid | 0 | - | - | - | - | |
aviptadil | 0 | - | - | - | - | |
bevacizumab | 0 | - | - | - | - | |
bismuth | 0 | - | - | - | - | |
BLD-2660 (calpain inhibitor) | 0 | - | - | - | - | |
calcium channel blocker | 0 | - | - | - | - | |
camostat mesilate | 0 | - | - | - | - | |
continuous positive airway pressure (CPAP) | 0 | - | - | - | - | |
cytokine adsorption | 0 | - | - | - | - | |
diammonium glycyrrhizinate | 0 | - | - | - | - | |
dipyridamol | 0 | - | - | - | - | |
DPP-4 inhibitor | 0 | - | - | - | - | |
enoxaparin | 0 | - | - | - | - | |
famotidine | 0 | - | - | - | - | |
kinin-kallikrein inhibitors | 0 | - | - | - | - | |
levamisole | 0 | - | - | - | - | |
metformin | 0 | - | - | - | - | |
natural killer (NK) cells | 0 | - | - | - | - | |
nicotin | 0 | - | - | - | - | |
nitric oxide (gas Inhalation or releasing solution) | 0 | - | - | - | - | |
ozonated autohemotherapy | 0 | - | - | - | - | |
pamrevlumab | 0 | - | - | - | - | |
povidone-iodine | 0 | - | - | - | - | |
proton pump inhibitors (PPI) | 0 | - | - | - | - | |
proxalutamide | 0 | - | - | - | - | |
PUL-042 inhalation solution | 0 | - | - | - | - | |
radiotherapy | 0 | - | - | - | - | |
selinexor | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
stem cells | 0 | - | - | - | - | |
tradipitant | 0 | - | - | - | - | |
tranilast | 0 | - | - | - | - | |
zinc | 0 | - | - | - | - |